although withdrew guidanc provid assess
impact updat forecast reflect signific near-term
headwind postpon elect procedur revis simpli best estim
junctur ultim unlik accur also adjust pt
valu recoveri year
revis estim reflect neg impact
updat forecast across coverag univers previou estim
inher aggress consid current environ accord
manag roughli sale deriv implant come
capit sale manag report revenu implant sale
highli lever elect surgeri use public comment compani file
deriv revenu estim geographi assum account
sale emea contribut asia pac provid china japan
region impact assumpt
hospit across adopt widespread elect surgeri postponement/
cancel polici sinc mid-march assum sell day
impact elect surgeri postpon western europ
revenu assum elect procedur volum also shut mid-march
itali elimin elect procedur begin march elect
procedur impact asia data point manag
team snn assum elect procedur volum shut
china japan south korea total revenu combin februari
march forecast revenu shortfal origin
region impact assumpt
assum hope conserv stunt year
elect surgeri volum throughout remain quarter assum
elect surgeri postpon region outsid asia
asia assum procedur postpon
expect procedur region except asia
recoveri start end year continu capit
sale anticip eu hospit repriorit capit budget
benefit syk medic busi bed provid headwind sale mako robot
surgic instrument rest capit portfolio forecast hit
previou revenu estim
recoveri assumpt
took simplist high-level approach revenu build assumpt
believ hospit begin recov return histor
product level throughout remaind patient backlog provid
tailwind hospit asc plan increas product vs pre-covid
level forecast organ revenu growth base
acceler organ revenu growth
pleas see page report import disclosur
outperform rate center belief diversifi busi model margin
expans initi strategi off-set continu price util
headwind ortho spine market expect deliv top-tier top-
bottom-lin growth vs med tech peer thu justifi premium valuat multipl
importantli think well posit ou emerg market expans
china lead way also see double-digit growth potenti trauma
extrem line instrument neurovascular devic among product
updat wright medic integr
detail mako spine applic
maintain share diversifi ortho
segment stabil spine
reduct cogs/year
 drive sale growth
irr year target close
better-than-expect ww share gain
ortho spine trauma busi
rapid expans better-than-
expect adopt emerg market
mark
ortho spine market worsen
share loss ortho spine mkt
portfolio outsid recon busi
fail provid suffici offset
ep growth fall short growth target
next five year
lead global medic technolog compani offer divers portfolio
reconstruct joint spine medic surgic neurovascular product compani
three major busi segment reconstruct medsurg neurotechnolog
spine product offer includ implant joint replac trauma spine-bas
surgeri surgic equip navig system endoscop commun
system patient handl emerg medic equip endovascular devic
treatment stroke coil treatment aneurysm major
global presenc look increas sale emerg market includ china
acquisit mako surgic late brought innov robot technolog
platform recon busi earli acquisit physio-
control bolster medsurg busi
oper expens reduct like balanc manag intern
opex forecast also challeng base current inform syk variabl vs fix
expens think manag tri posit compani come
end crisi posit strength therefor assum invest
sale market modestli temper turn expect
recov sg leverag return
regain momentum recoveri period estim revis
drive pt
lower pt base ep estim given
med-tech multipl contract ww pandem impact downward
revis estim believ share deserv premium
valuat peer given top tier revenu growth profil normal period
compani report thomson eikon cowen compani
mm except ex-med devic gener oper profit profit includ net non-gaap net earn per non-gaap earn per earn per cowen
compani report cowen compani
growth currenc growth currenc growth currenc growth currenc state growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc state growth currenc growth currenc cowen
compani report cowen compani
growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc cowen
compani report cowen compani
growth currenc growth currenc growth currenc growth currenc growth currenc growth currenc spine growth currenc growth growth currenc growth currenc growth growth currenc inorgan sell day report growth report growth ex-inorgan sell organ growth organ growth ex-fx ex-sel cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
orthoped industri risk continu util pressur account
organ play bigger role health care deliveri competit dynam global
potenti regulatori delay reject failur devic clinic trial econom
sensit price pressur and/or weaken consum demand develop market
econom and/or polit uncertainti emerg market intellectu properti
deeper util pressur europ competit dynam global
potenti regulatori delay reject failur devic clinic trial econom
sensit price pressur and/or weaken demand develop market econom
and/or polit uncertainti emerg market fluctuat foreign exchang
